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Recognition of antigen by CD4
 
 
 
 T cells requires pre-
sentation of short peptide fragments in the context of het-
erodimeric MHC class II molecules (1, 2). Antigen presen-
tation by MHC class II molecules is pivotal to the
induction of adaptive immune responses, peripheral toler-
ance, and central tolerance, as well as being required for
CD4
 
 
 
 T cell survival (1–3). Constitutive expression of
MHC class II molecules is restricted to APCs: B cells, den-
dritic cells and macrophages; and cortical thymic epithelial
cells (cTECs), where MHC class II molecules mediate pos-
itive selection of CD4
 
 
 
 T cells (4). The expression of
MHC class II on APCs can be further upregulated in re-
sponse to inflammatory mediators such as IFN-
 
  
 
and LPS.
These stimuli are also able to induce MHC class II expres-
sion on other cell types, e.g., epithelial cells and endothelial
cells. However, the precise role of inducible MHC class II
expression on non-APCs remains unclear, although it has
been implicated in many autoimmune diseases, allograft re-
jection, and clearance of pathogens from the body (5–7).
Regulation of MHC class II expression at the transcrip-
tional level is complex, and the class II transactivator (CIITA)
is a non–DNA-binding transcriptional activator that plays a
key role in this process (8, 9). CIITA was first identified in
complementation studies as one of the genes responsible for
bare lymphocyte syndrome in humans, a congenital disease
in which patients lack both constitutive and inducible ex-
pression of MHC class II molecules (10). CIITA is thought
to mediate transcriptional activation by interacting with a
large number of DNA-binding proteins to form a complex
that initiates transcription (8, 9). These proteins include
RFX5, RFXANK, CREB, and NF-Y, and they bind spe-
cific regions in the MHC class II promoter, known as the
W, X, and Y boxes (8, 9). It is believed that CIITA pro-
vides the specificity for the expression of MHC class II, as
the other transcription factors present in the initiating com-
plex are expressed ubiquitously (8, 9).
The role of CIITA in the regulation of MHC class II ex-
pression has been further dissected in many in vitro and in
vivo studies. Transfection of CIITA into cell lines and pri-
mary cells that normally lack MHC class II expression has
been shown to be sufficient to induce MHC class II ex-
pression, while in CIITA-deficient animals, MHC class II
mRNA is barely detectable and cell surface expression is
absent on the majority of cells (11–13). Further evidence
indicating the importance of CIITA in regulating MHC
class II comes from the observation that the level of expres-
sion of MHC class II correlates directly with that of CIITA
(14). In addition, the loss of MHC class II expression on B
cells as they differentiate into plasma cells has been shown
to be concomitant with a loss of CIITA (15), and the ab-
sence of MHC class II expression in trophoblasts has been
reported to be accompanied by a lack of CIITA (13).
Taken together, these observations have lead to the con-
clusion that CIITA acts as the master regulator of MHC
class II expression (8, 9).
The major mechanism by which CIITA expression is
regulated is transcriptional. Four independent promoters of
the CIITA gene (
 
Mhc2ta
 
) have been identified in humans
and three in mice (16). Initiation of transcription from each
promoter generates distinct gene products, each differing at
their NH
 
2
 
 terminus, the significance of which is unknown
at present (8, 9). Differential promoter usage has been ob-
served in distinct cell types, with promoter I (pI) being
highly specific for DCs, B cells primarily using promoter III
 
(pIII), and promoter IV (pIV) mediating IFN-
 
 
 
–induced
upregulation of CIITA in APCs as well as other cell types
(16). This specificity of promoter usage is not complete,
however, as pIII transcripts have been observed in some
populations of DCs, and although pIV is the most impor-
tant promoter for IFN-
 
 
 
–induced upregulation, pIII has
also been shown to be IFN-
 
 
 
 responsive (17).
Studies of the molecular mechanisms regulating the re-
sponsiveness of pIV to IFN-
 
 
 
 have provided evidence for
the cooperative involvement of a number of transcription
factors, in particular, the IFN-
 
 
 
 induced transcription fac-
tors signal transducer and activator of transcription-1
(STAT-1) and IFN regulatory factor-1 (IRF-1) and the
constitutively expressed upstream stimulating factor-1
(USF-1) (17–19). However, little is known about the bio-
logical significance of IFN-
 
 
 
–induced upregulation of
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MHC class II on non-APCs, as previous studies have been
unable to separate this from the expression of MHC class II
by APCs (12, 20). In this issue, Waldburger et al. (21) cir-
cumvent this problem by generating mice lacking pIV of
CIITA, in which the expression of MHC class II on the
surfaces of APCs is segregated from its IFN-
 
 
 
–inducible
expression on nonhematopoietic cells. In addition, these
mice provide the first definitive evidence that differential
CIITA promoter usage does indeed play an important
physiological role.
Perhaps the most surprising observation of Waldburger
et al. (21) is that constitutive expression of MHC class II on
cTECs is eliminated in pIV-deficient animals. MHC class
II expression on cTECs has been shown to be independent
of IFN-
 
 
 
 signaling, as CD4
 
 
 
 T cell positive selection is not
impaired in IFN-
 
 
 
–deficient or IFN-
 
 
 
 receptor–deficient
animals (22, 23). This suggests that the pathway leading to
the initiation of transcription from pIV in cTECs must dif-
fer from that induced by IFN-
 
 
 
 in other nonhematopoietic
cells. Further evidence for this hypothesis comes from the
observation that positive selection of CD4
 
 
 
 T cells occurs
normally in animals deficient in either of the two transcrip-
tion factors shown to be responsible for initiating pIV tran-
scription in response to IFN-
 
 
 
, STAT-1, or IRF-1 (24,
25). However, IRF-1 has been shown to initiate pIV tran-
scription independently of STAT-1 (17), and therefore,
analysis of positive selection in IRF-1 
 
 
 
 STAT-1 double-
deficient animals would be necessary to completely rule out
any role for these transcription factors in regulating consti-
tutive MHC class II expression on cTECs.
Thymic stromal cell lines lack MHC class II expression,
and freshly isolated cTECs lose MHC class II expression if
cultured as a cell suspension or a two-dimensional mono-
layer. However, reexpression can be induced on these cells
by exposure to IFN-
 
 
 
, thus indicating that the pathway
mediating IFN-
 
 
 
–induced CIITA expression can be func-
tional in cTECs (26–28). Interestingly, MHC class II ex-
pression on cTECs is maintained in the absence of IFN-
 
 
 
 if
they are cultured as three-dimensional reaggregates known
as reaggregate thymus organ cultures (RTOCs) (29). This
implies that MHC class II expression is maintained on
cTECs by a signal or stimulus, distinct from IFN-
 
 
 
, that
they perceive only in vivo or in three-dimensional reaggre-
gates (Fig. 1).
Developing thymocytes are one potential cell type that
may provide a stimulus to maintain MHC class II on
cTECs. However, cTECs isolated from recombination-acti-
vating gene (RAG)
 
 
 
/
 
 
 
 mice have been shown to express
Figure 1. Pathways initiating transcription from pIV of the CIITA gene. Transcription from pIV is initiated in many nonhematopoietic cells, including
cTECs, in response to IFN-  and involves upregulation of the transcription factors STAT-1 and IRF-1. These factors in combination with USF-1 form
a complex capable of initiating transcription. A second pathway drives transcription from pIV in cTECs and is responsible for the constitutive expression
of MHC class II on these cells in vivo. The stimuli and signal transduction pathway involved in this second pathway are at present unknown, and here we
suggest that this stimulus may be provided by either cell–cell contact between cTECs or the release of a short acting soluble factor from cTECs. 
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MHC class II and support positive selection of fetal liver
cells, implying that neither double-positive thymocytes nor
the more mature single-positive thymocytes are required to
maintain cTEC MHC class II expression (30). A role for
double-negative thymocytes, cells readily detectable in
RAG
 
 
 
/
 
 
 
 thymi, in maintaining MHC class II expression
on cTECs has also been ruled out by in vitro experiments.
MHC class II molecules can be detected on epithelial cells
from embryonic thymic lobes cultured in the presence of
deoxyguanosine (31). This treatment eliminates all thy-
mocytes, including those that are double negative, indicat-
ing that these cells are not essential for maintaining cTEC
MHC class II expression. Similarly, it has been observed
that mesenchymal cells play no role in maintenance of
MHC class II on cTECs, as surface expression was not lost
in RTOCs containing only purified cTECs and thy-
mocytes (29). These observations suggest that a signal pro-
vided either by cell–cell interactions between the cTECs or
by a short acting soluble factor produced by cTECs is re-
quired to maintain their expression of MHC class II.
One potential candidate for a soluble factor, secreted by
thymic epithelial cells, that could induce constitutive MHC
class II expression on cTECs is IL-7. However, IL-7 is un-
likely to be the sole factor required for maintaining MHC
class II expression on cTECs, as MHC class II is expressed at
wild-type levels on the surfaces of cTECs isolated from IL-
7–deficient mice (30). A role for other soluble factors has
not been studied per se; however, the normal development
of CD4
 
 
 
 T cells in a wide number of cytokine and cytokine
receptor knockout animals, e.g., IL-2, IL-4, IL-15, and IL-
15R
 
 
 
, implies that MHC class II expression on cTECs is
unaffected by their absence (32). These observations pro-
vide no evidence to suggest that one specific soluble factor is
essential for MHC class II expression on cTECs. However,
they do not rule out redundancy among cytokines or a role
for alternative or potentially novel cytokines.
The generation of reaggregates from cTECs maintained
as a monolayer, i.e., MHC class II–negative cTECs, would
allow studies of the role of specific cTEC interactions in in-
ducing and maintaining the expression of MHC class II to
be performed. Thus far, studies of this kind have been lim-
ited to an analysis of whether such reaggregates are able to
support positive selection of CD4
 
 
 
 T cells, which they are
not (Anderson, G., personal communication). However,
the presence or absence of CD4
 
 
 
 T cell selection is not ap-
propriate as a readout for reexpression of MHC class II on
cTECs after culture, as it has been shown that other mole-
cules required for positive selection besides MHC class II
are lost when cTECs are cultured on a monolayer of feeder
cells (33). The hypothesis that ligation of a cell surface mol-
ecule, other than the IFN-
 
 
 
 receptor, can initiate MHC
class II expression is not without precedence. It has been
reported that expression of MHC class II molecules on hu-
man thyroid follicular cells, which are normally HLA-DR
negative, can be induced by culturing the cells in the pres-
ence of lectins (34), implying that non-APCs can be stimu-
lated to express MHC class II by mechanisms other than
IFN-
 
 
 
.
 
The observation of Waldburger et al. (21) that in the CIITA
pIV
 
 
 
/
 
 
 
 mouse, MHC class II expression on cTECs is abro-
gated, suggests that in cTECs CIITA transcription is initi-
ated from pIV both in response to IFN-
 
 
 
 and in response
to an as yet unidentified second stimulus or signal (Fig. 1).
It is not clear, however, whether these two pathways are
redundant or, in fact, whether both of these pathways op-
erate to maintain MHC class II expression on cTECs in
vivo. The role of the IFN-
 
 
 
 pathway is particularly ques-
tionable, as few studies have investigated expression of this
cytokine in the thymus. In one report, mRNA for IFN-
 
 
 
was detected in the fetal thymus on days 14–20 of gesta-
tion, with levels peaking at day 16 and declining thereafter
(35). Whether this is translated into a physiologically signif-
icant level of protein in terms of maintaining cTEC MHC
class II expression is at present unknown. Additionally, the
time frame studied in this report was short, and it is not
known whether levels of IFN-
 
 
 
 mRNA persist. Therefore,
at present it is difficult to determine the importance of
IFN-
 
 
 
 in maintaining MHC class II expression on cTECs.
Roles for STAT-1, IRF-1, and USF-1 in regulating the re-
sponse to IFN-
 
 
 
 have been studied in detail, and this has
been discussed above. However, their involvement in the
alternative pathway responsible for maintaining constitutive
MHC class II expression on cTECs has not been investi-
gated. As a result, studies to define this signaling pathway
and the initiating stimulus will be essential for furthering
our understanding of the mechanisms of thymocyte devel-
opment. The existence of a novel pIV-dependent pathway
for regulating CIITA and MHC class II expression in
cTECs, as implied by the studies of Waldburger et al. (21),
indicate that the regulation of CIITA and MHC class II ex-
pression is far more complex than had previously been
thought.
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